Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$8.80

-0.66 (-6.98%)

16:26
11/06/18
11/06
16:26
11/06/18
16:26

Iovance says patient dosing continues in C-145-04 study

Iovance Biotherapeutics said in today's earnings release, "Patient dosing continues in the C-145-04 study for cervical carcinoma. The company recently dosed its first patient in Europe. This study design is based on a Simon's two-stage design. The first stage has been completed and enrollment in the study continues with target enrollment of 47. Preliminary data for 15 patients yielded an ORR of 27% with an early look at the DOR ranging from 2.4 to 2.5+ months. Patients in the study had a median of five prior therapies. The safety findings from this study remain consistent with previous reports. The protocol for this study has been amended to limit the number of prior therapies to no more than three and to exclude patients who have been treated with prior immunotherapy. Iovance anticipates providing an update on this study at an upcoming medical meeting in 2019. In the C-145-03 study for head and neck cancer, to date, preliminary data for 13 patients has yielded an ORR of 31% with the DOR ranging from 2.8 to 7.6 months. The safety findings from this study is also consistent with previous reports. Patients in the study had a median of three prior therapies. For the study in NSCLC, IOV-LUN-201, in collaboration with MedImmune, the company amended the protocol to eliminate the TIL monotherapy cohort and patients will now be enrolled for treatment with LN-145 and durvalumab. There are currently nine sites active for this trial. The study in PD-1 naive melanoma and head and neck patients with TIL in combination with pembrolizumab, and LN-145 as monotherapy in NSCLC patients (IOV-COM-202) is open to enrollment with two sites active."

  • 06

    Nov

  • 20

    Nov

IOVA Iovance Biotherapeutics
$8.80

-0.66 (-6.98%)

09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.
11/06/18
WELS
11/06/18
NO CHANGE
WELS
Outperform
Iovance data supportive of potential approval, says Wells Fargo
The 38% response rate and duration greater than six months seen in this morning's abstract data for tumor-infiltrating lymphocyte therapeutic lifleucel in PD1 experienced metastatic melanoma are "highly differentiated from other cell therapies in solid tumors and supportive of potential approval if confirmed by pivotal study," Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst keeps an Outperform rating on shares of Iovance Biotherapeutics. The stock in morning trading is down 10%, or 99c, to $8.46.

TODAY'S FREE FLY STORIES

CYTK

Cytokinetics

$7.52

-0.17 (-2.21%)

, AMGN

Amgen

$187.14

0.17 (0.09%)

14:27
02/20/19
02/20
14:27
02/20/19
14:27
Recommendations
Cytokinetics, Amgen analyst commentary  »

Piper reiterates…

CYTK

Cytokinetics

$7.52

-0.17 (-2.21%)

AMGN

Amgen

$187.14

0.17 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 28

    Feb

  • 01

    Mar

GG

Goldcorp

$11.52

0.25 (2.22%)

14:25
02/20/19
02/20
14:25
02/20/19
14:25
Options
Goldcorp call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
02/20/19
02/20
14:25
02/20/19
14:25
General news
FX Action: The Dollar »

FX Action: The Dollar…

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$172.67

1.72 (1.01%)

14:23
02/20/19
02/20
14:23
02/20/19
14:23
Periodicals
Samsung unveils new foldable phone called Galaxy Fold, Verge reports »

At Samsung's Galaxy…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$172.67

1.72 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

FDP

Fresh Del Monte

$29.80

0.53 (1.81%)

14:20
02/20/19
02/20
14:20
02/20/19
14:20
Hot Stocks
Fresh Del Monte board suspends quarterly cash dividend »

Fresh Del Monte Produce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
02/20/19
02/20
14:20
02/20/19
14:20
General news
FOMC minutes to Januayr 29, 30 meeting: »

FOMC minutes to Januayr…

NXTM

NxStage Medical

$29.99

0.35 (1.18%)

, FMS

Fresenius Medical

$40.17

1.79 (4.66%)

14:18
02/20/19
02/20
14:18
02/20/19
14:18
Hot Stocks
FTC requires NxStage, Fresenius Medical to divest bloodline tubing assets »

The Federal Trade…

NXTM

NxStage Medical

$29.99

0.35 (1.18%)

FMS

Fresenius Medical

$40.17

1.79 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 05

    Mar

  • 12

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/20/19
02/20
14:17
02/20/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/20/19
02/20
14:16
02/20/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$54.65

-0.65 (-1.18%)

14:15
02/20/19
02/20
14:15
02/20/19
14:15
Options
Etsy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

14:09
02/20/19
02/20
14:09
02/20/19
14:09
General news
'Almost all' Fed members wanted to announce plan to stop reducing assets »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

14:06
02/20/19
02/20
14:06
02/20/19
14:06
General news
Fed saw 'variety of considerations' for 'patient approach to monetary policy' »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

14:05
02/20/19
02/20
14:05
02/20/19
14:05
General news
Fed to continue monitoring economic developments for outlook implications »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

14:02
02/20/19
02/20
14:02
02/20/19
14:02
General news
Fed sees 'sustained expansion of economic activity' as most likely outcome »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$29.97

0.7 (2.39%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Hot Stocks
Breaking Hot Stocks news story on Fresh Del Monte »

Fresh Del Monte trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.13

-2.04 (-8.10%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Options
Dip buyer in Bausch Health Companies »

Dip buyer in Bausch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

13:59
02/20/19
02/20
13:59
02/20/19
13:59
Periodicals
Audi plans to cut 10% of management positions, Reuters reports »

Audi (AUDVF),…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$146.31

-15.45 (-9.55%)

13:58
02/20/19
02/20
13:58
02/20/19
13:58
On The Fly
Trade Desk slides after analyst cuts rating ahead of quarterly results »

Shares of Trade Desk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 06

    Mar

  • 06

    Mar

UA

Under Armour

$19.15

-0.23 (-1.19%)

13:55
02/20/19
02/20
13:55
02/20/19
13:55
Options
Under Armour put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

PM

Philip Morris

$85.42

2 (2.40%)

13:50
02/20/19
02/20
13:50
02/20/19
13:50
Earnings
Philip Morris repeats Q1 reported diluted EPS view of $1.00, consensus $1.01 »

As communicated on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.42

2 (2.40%)

13:49
02/20/19
02/20
13:49
02/20/19
13:49
Earnings
Philip Morris reaffirms FY19 reported diluted EPS guidance of at least $5.37 »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Fed's Kaplan said a weaker business outlook is the reason for caution on rates »

Fed's Kaplan said a…

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

MDR

McDermott

$7.80

0.44 (5.98%)

13:40
02/20/19
02/20
13:40
02/20/19
13:40
Options
Bullish option play in McDermott as shares rally ahead of earnings »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 12

    Mar

  • 17

    Mar

  • 18

    Mar

  • 02

    May

STAG

STAG Industrial

$28.24

-0.59 (-2.05%)

13:34
02/20/19
02/20
13:34
02/20/19
13:34
Recommendations
STAG Industrial analyst commentary  »

STAG Industrial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.